Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Case Report

Insulin Autoimmune Syndrome After Exposure to Clopidogrel: A Case Report

Author(s): Yihong Jiang, Lihua Wang, Fanghong Shi, Huan Zhou, Jun Zheng, Jie Cai, Shuang Yang, Jing Ma* and Wei Liu*

Volume 20, Issue 8, 2020

Page: [1355 - 1362] Pages: 8

DOI: 10.2174/1871530320666191220111615

Price: $65

Abstract

Background: Insulin autoimmune syndrome (IAS) is a rare cause of hypoglycemia that is characterized by hyperinsulinemia, hypoglycemia, and a high autoantibody titer. About 50% of patients with IAS have taken a medication containing sulfhydryl (-SH) groups. We present a case of IAS that developed after taking clopidogrel, a drug with an active metabolite that contains an SH-group.

Case Report: IAS was suspected in a 63-year-old Chinese man because of high concentrations of insulin and C-peptide during hypoglycemic episodes, and positivity for anti-insulin autoantibody (IAA). During his first episode of hypoglycemia, no trigger medication was identified and prednisone therapy was effective. However, imaging examination revealed a colonic carcinoma and the patient was discharged to undergo surgery. He had no episodes of hypoglycemia for 10 weeks after discontinuation of the prednisone, but then hypoglycemia recurred. A review of his medication revealed that he had taken a 10-day course of clopidogrel just before the recurrence. Therefore, a specialized multidisciplinary team consisting of endocrinologists, dieticians, and clinical pharmacists took charge of his management. Prednisone therapy was restarted and tapered off over 16 weeks. The patient also consumed small, frequent, low-carbohydrate meals and was instructed to avoid trigger medications. No further episodes of hypoglycemia were detected. His insulin and C-peptide concentrations and his anti-IAA index normalized during the follow-up period.

Conclusion: SH-group-containing drugs might induce or exacerbate hypoglycemia in patients with a history of IAS. Furthermore, patients with IAS can benefit from multidisciplinary team management. We suggest herein an evaluation process for patients suspected of IAS.

Keywords: Insulin autoimmune syndrome, hypoglycemia, anti-insulin autoantibody, clopidogrel, multidisciplinary team, prednisone.

« Previous
Graphical Abstract
[1]
Uchigata, Y.; Hirata, Y. Insulin autoimmune syndrome (IAS, Hirata disease). Ann. Med. Interne (Paris), 1999, 150(3), 245-253.
[PMID: 10445096]
[2]
Hirata, Y.; Uchigata, Y. Insulin autoimmune syndrome in Japan. Diabetes Res. Clin. Pract., 1994, 24(Suppl.), S153-S157.
[http://dx.doi.org/10.1016/0168-8227(94)90243-7] [PMID: 7859599]
[3]
Uchigata, Y.; Hirata, Y.; Iwamoto, Y. Drug-induced insulin autoimmune syndrome. Diabetes Res. Clin. Pract., 2009, 83(1), e19-e20.
[http://dx.doi.org/10.1016/j.diabres.2008.10.015] [PMID: 19070385]
[4]
Lupsa, B.C.; Chong, A.Y.; Cochran, E.K.; Soos, M.A.; Semple, R.K.; Gorden, P. Autoimmune forms of hypoglycemia. Medicine (Baltimore), 2009, 88(3), 141-153.
[http://dx.doi.org/10.1097/MD.0b013e3181a5b42e] [PMID: 19440117]
[5]
Censi, S.; Mian, C.; Betterle, C. Insulin autoimmune syndrome: from diagnosis to clinical management. Ann. Transl. Med., 2018, 6(17), 335.
[http://dx.doi.org/10.21037/atm.2018.07.32] [PMID: 30306074]
[6]
Uchigata, Y.; Eguchi, Y.; Takayama-Hasumi, S.; Omori, Y. Insulin autoimmune syndrome (Hirata disease): Clinical features and epidemiology in Japan. Diabetes Res. Clin. Pract., 1994, 22(2-3), 89-94.
[http://dx.doi.org/10.1016/0168-8227(94)90040-X] [PMID: 8200300]
[7]
Veltroni, A.; Zambon, G.; Cingarlini, S.; Davi, M.V. Autoimmune hypoglycaemia caused by alpha-lipoic acid: A rare condition in Caucasian patients. Endocrinology, diabetes & metabolism case reports, 2018.
[http://dx.doi.org/10.1530/EDM-18-0011]
[8]
Gullo, D.; Evans, J.L.; Sortino, G.; Goldfine, I.D.; Vigneri, R. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking α-lipoic acid. Clin. Endocrinol. (Oxf.), 2014, 81(2), 204-209.
[http://dx.doi.org/10.1111/cen.12334] [PMID: 24111525]
[9]
Yamada, E.; Okada, S.; Saito, T.; Osaki, A.; Ozawa, A.; Yamada, M. Insulin autoimmune syndrome during the administration of clopidogrel. J. Diabetes, 2016, 8(4), 588-589.
[http://dx.doi.org/10.1111/1753-0407.12385] [PMID: 26847582]
[10]
Rajpal, A.; Kassem, L.S.; Moscoso-Cordero, M.; Arafah, B.M. Clopidogrel-Induced Insulin Autoimmune Syndrome: A Newly Recognized Cause of Hypoglycemia in a Patient Without Diabetes. J. Endocr. Soc., 2017, 1(9), 1217-1223.
[http://dx.doi.org/10.1210/js.2017-00316] [PMID: 29264578]
[11]
Taylor, S.I.; Barbetti, F.; Accili, D.; Roth, J.; Gorden, P. Syndromes of autoimmunity and hypoglycemia. Autoantibodies directed against insulin and its receptor. Endocrinol. Metab. Clin. North Am., 1989, 18(1), 123-143.
[http://dx.doi.org/10.1016/S0889-8529(18)30392-X] [PMID: 2645123]
[12]
Uchigata, Y.; Kuwata, S.; Tokunaga, K.; Eguchi, Y.; Takayama-Hasumi, S.; Miyamoto, M.; Omori, Y.; Juji, T.; Hirata, Y. Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet, 1992, 339(8790), 393-394.
[http://dx.doi.org/10.1016/0140-6736(92)90080-M] [PMID: 1346661]
[13]
Church, D.; Cardoso, L.; Bradbury, S.; Clarke, C.; Stears, A.; Dover, A.; Halsall, D.; Semple, R. Diagnosis of insulin autoimmune syndrome using polyethylene glycol precipitation and gel filtration chromatography with ex vivo insulin exchange. Clin. Endocrinol. (Oxf.), 2017, 86(3), 347-353.
[http://dx.doi.org/10.1111/cen.13179] [PMID: 27588366]
[14]
Willard, D.L.; Stevenson, M.; Steenkamp, D. Type B insulin resistance syndrome. Curr. Opin. Endocrinol. Diabetes Obes., 2016, 23(4), 318-323.
[http://dx.doi.org/10.1097/MED.0000000000000263] [PMID: 27254267]
[15]
Redmon, J.B.; Nuttall, F.Q. Autoimmune hypoglycemia. Endocrinol. Metab. Clin. North Am., 1999, 28(3)603-618, vii. [vii.]..
[http://dx.doi.org/10.1016/S0889-8529(05)70090-6] [PMID: 10500933]
[16]
Yuan, T.; Li, J.; Li, M.; Li, N.; Duan, L.; Ping, F.; Li, W.; Wang, L.; Zhao, W. Insulin autoimmune syndrome diagnosis and therapy in a single Chinese center. Clin. Ther., 2019, 41(5), 920-928.
[http://dx.doi.org/10.1016/j.clinthera.2019.03.009] [PMID: 30992145]
[17]
Saxon, D.R.; McDermott, M.T.; Michels, A.W. Novel management of insulin autoimmune syndrome with rituximab and continuous glucose monitoring. J. Clin. Endocrinol. Metab., 2016, 101(5), 1931-1934.
[http://dx.doi.org/10.1210/jc.2016-1097] [PMID: 26982011]
[18]
Dozio, N.; Scavini, M.; Beretta, A.; Sarugeri, E.; Sartori, S.; Belloni, C.; Dosio, F.; Savi, A.; Fazio, F.; Sodoyez, J.C.; Pozza, G. Imaging of the buffering effect of insulin antibodies in the autoimmune hypoglycemic syndrome. J. Clin. Endocrinol. Metab., 1998, 83(2), 643-648.
[http://dx.doi.org/10.1210/jc.83.2.643] [PMID: 9467587]
[19]
Philippon, M.; Sejil, S.; Mugnier, M.; Rocher, L.; Guibergia, C.; Vialettes, B.; Delenne, B. Use of the continuous glucose monitoring system to treat insulin autoimmune syndrome: quantification of glucose excursions and evaluation of treatment efficacy. Diabet. Med., 2014, 31(7), e20-e24.
[http://dx.doi.org/10.1111/dme.12418] [PMID: 25077287]
[20]
Church, D.; Cardoso, L.; Kay, R.G.; Williams, C.L.; Freudenthal, B.; Clarke, C.; Harris, J.; Moorthy, M.; Karra, E.; Gribble, F.M.; Reimann, F.; Burling, K.; Williams, A.J.K.; Munir, A.; Jones, T.H.; Führer, D.; Moeller, L.C.; Cohen, M.; Khoo, B.; Halsall, D.; Semple, R.K. Assessment and management of anti-insulin autoantibodies in varying presentations of insulin autoimmune syndrome. J. Clin. Endocrinol. Metab., 2018, 103(10), 3845-3855.
[http://dx.doi.org/10.1210/jc.2018-00972] [PMID: 30085133]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy